| ²é¿´: 1094 | »Ø¸´: 1 | ||
liuxing3982ľ³æ (ÕýʽдÊÖ)
|
[ÇóÖú]
ÇóÖú½«ÖÐÎÄ·Òë³ÉÓ¢ÎĵÄÎÄÕÂÕªÒª£¬²»Ê¤¸Ð¼¤
|
| [Õª Òª] ±¾ÎÄÖ÷ÒªÊǶԼÓÃ×ùµÄºÏ³É¹¤ÒÕ½øÐиĽø£¬ÓÅ»¯¸üÊʺϷŴóÉú²úµÄ¹¤ÒÕ£¬Í¨¹ý¸Ä±äÖмäÌåµÄ´¿»¯·½·¨£¬¸ü»»·´Ó¦ÊÔ¼Á£¬Ê¹Õû¸ö·´Ó¦¹ý³Ì¸ü°²È«»·±££¬³É±¾¸üµÍ£»¸Ã·ÏßÒÔ9-ÍÑÑõ-9-ͬÐͺìÃ¹ËØ A(E)ë¿ÎªÔÁÏ£¬ÔÚ¼îÐÔ´ß»¯¼ÁµÄ×÷ÓÃÏÂÉú³É9-ÍÑÑõ-9-ͬÐͺìÃ¹ËØ A(Z)ë¿£¬ÔÙ¾¹ý±´¿ËÂüÖØÅÅ·´Ó¦Éú³ÉºìÃ¹ËØÑǰ²ÃÑ£¬È»ºó¾¹ýÅðÇâ»¯ÄÆ»¹ÔÉú³É9-ÍÑÑõ-8a-µªÔÓ-8a-ͬÐͺìÃ¹ËØA£¬×îºó¾¹ý»¹Ô°·»¯·´Ó¦µÃµ½¼ÓÃ×Ã¹ËØ£»²¢ÇÒÓÃÒÒëæ×÷ÈܼÁÅàÑø³ö¼ÓÃ×Ã¹ËØµ¥¾§£¬¸Ãµ¥¾§Êý¾Ý±»Ó¢¹ú½£Çž§ÌåѧÊý¾Ý¿âÊÕ¼£¬¾§ÌåµÄCCDCºÅΪ1913324£»¼ÓÃ×Ã¹ËØµÄXÉäÏßÑÜÉäµ¥¾§½á¹¹²â¶¨±íÃ÷£¬Æä½á¹¹Îªµ¥Ð±¾§Ïµ£¬C2¿Õ¼äȺ£¬¾ßÓÐÊÖÐÔ£¬¾§°û²ÎÊý£ºa[Å]=27.536(6)£¬b[Å]=9.6582(19)£¬c[Å]=18.529(4)£¬¦Á[˚]=90¦Â[˚]˚=114.00(3)£¬¦Ã[˚]=90V[Å3]=4501.6(15)£¬Z=4£¬Dc[mg/m3]=1.177£¬[mm¨C1]=0.086£¬F(000)=1750£¬GOF=1.043£¬Rint=0.0417£¬R1a, wR2b[I >2¦Ò(I)]=0.0492,0.1291£¬Residuals [eÅ-3]= 0.0564, 0.1354. ¼ÓÃ×Ã¹ËØ¾§Ð͵ÄÈ·¶¨ÎªºóÐøÑо¿¼ÓÃ×Ã¹ËØÖÆ¼ÁмÁÐ͵ȷ½ÃæÌṩÐÂÑ¡Ôñ¡£ |
» ²ÂÄãϲ»¶
²ÄÁϵ÷¼Á
ÒѾÓÐ10È˻ظ´
Ò»Ö¾Ô¸¹þ¶û±õ¹¤Òµ´óѧ085600Ó¢Ò»Êý¶þ337·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
288Çóµ÷¼Á Ò»Ö¾Ô¸¹þ¹¤´ó ²ÄÁÏÓ뻯¹¤
ÒѾÓÐ11È˻ظ´
Çóµ÷¼Á£¬Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ £¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶
ÒѾÓÐ9È˻ظ´
±¾¿Æ211£¬293·ÖÇëÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
085400µç×ÓÐÅÏ¢319Çóµ÷¼Á£¨½ÓÊÜ¿çרҵµ÷¼Á£©
ÒѾÓÐ5È˻ظ´
268Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
һ־Ը˫·Ç085502£¬267·Ö£¬¹ýËļ¶Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
Ò»Ö¾Ô¸085404£¬×Ü·Ö291£¬Ëļ¶Òѹý£¬Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´

Inorg@USF
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 4236.3
- É¢½ð: 10
- ºì»¨: 10
- Ìû×Ó: 329
- ÔÚÏß: 133Сʱ
- ³æºÅ: 291411
- ×¢²á: 2006-10-29
- ÐÔ±ð: GG
- רҵ: ÎÞ»úºÏ³ÉºÍÖÆ±¸»¯Ñ§
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
|
ÊÔÊÔ°¡£¬ Abstract This article is mainly to improve the synthesis process of Candida, optimize the process that is more suitable for scale-up production. By changing the purification method of intermediates and replacing the reaction reagents, the entire reaction process is safer and more environmentally friendly, and lower cost. The scheme is to choose 9-deoxy-9-homo-erythromycin A(E) oxime as raw material, synthesized 9-deoxy-9-homo-erythromycin A(Z) oxime with alkaline catalyst, and produced erythromycin sulfonate through Beckmann rearrangement reaction, then reduced it with sodium borohydride to convert to 9-deoxy-8a-aza-8a-homoerythromycin A, finally undergoed reductive amination reaction to obtain gamimycin. THe single crystal of gamimycin was obtained with acetonitrile as a solvent. The crystal data is indexed in the Cambridge Crystallographic Database of the United Kingdom. The CCDC number of the crystal was 1913324; X-ray diffraction single crystal structure determination of gamimycin showed that its structure was a monoclinic system, C2 Space group, with chirality, unit cell parameters: a[Å]=27.536(6), b[Å]=9.6582(19), c[Å]=18.529(4), ¦Á[˚]=90¦Â [˚]˚=114.00(3), ¦Ã[˚]=90V[Å3]=4501.6(15), Z=4, Dc[mg/m3]=1.177, [mm¨C1]=0.086, F (000)=1750, GOF=1.043, Rint=0.0417, R1a, wR2b[I >2¦Ò(I)]=0.0492,0.1291, Residuals [eÅ-3]= 0.0564, 0.1354. Determination of the crystal form of Gamimycin provides a new option for the follow-up study of new dosage forms of Gamimycin preparations. |

2Â¥2020-06-21 10:06:17














»Ø¸´´ËÂ¥